A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
May 31, 2022
End Date
May 15, 2027
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
May 31, 2022
End Date
May 15, 2027